공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

중국의 경장영양 시장 분석(2021-2025년)

Investigation Report on China´s Enteral Nutrition Market 2021-2025

리서치사 China Research and Intelligence
발행일 2021년 06월 상품 코드 1010193
페이지 정보 영문 50 Pages
가격
US $ 2,600 ₩ 3,093,000 Unprintable PDF (Single User License)
US $ 3,900 ₩ 4,640,000 Printable & Editable PDF (Enterprisewide License)


중국의 경장영양 시장 분석(2021-2025년) Investigation Report on China´s Enteral Nutrition Market 2021-2025
발행일 : 2021년 06월 페이지 정보 : 영문 50 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

경장영양은 주로 식욕 부진 및 기계적 위장 기능 장애, 중증질병, 영양실조 등의 관련 질환이 있는 환자의 술전 섭식에 사용됩니다. Fresenius Kabi에 의해 개발되어 1995년에 중국에서도 출시되었습니다. 2020년 시점에 8사의 제조업체가 중국 시장에 참여하고 있습니다.

중국내 경장영양의 판매량은 2016-2019년 해마다 꾸준히 증가하고 있습니다. 그러나 2020년에는 COVID-19 감염 확대가 병원의 진단·치료 서비스에 크게 영향을 미쳤으므로 경장영양 시장 규모도 약간 감소하며, 2020년에는 11억 5500만 위안에 달했습니다. 또한 2016-2020년 CAGR은 약 6.5%를 기록했습니다.

향후 COVID-19의 억제 및 의료 서비스 개선 등의 요인에 의해 중국내 경장영양 시장 규모는 2021-2025년 회복할 전망입니다.

중국의 경장영양 시장을 분석했으며, 제품 개요 및 인허가 상황, 전체적인 시장 규모의 동향 전망, 지역별 상세 동향, 시장 가격의 동향 전망, 주요 기업의 개요와 시장 점유율, 주요 시장 촉진·억제요인, 신종 코로나바이러스 감염증(COVID-19)의 영향 등의 정보를 정리하여 전해드립니다.

목차

제1장 경장영양의 관련 개념

  • 경장영양의 적응증
  • 중국내 경장영양의 개발 동향
  • 중국 정부의 경장영양 승인 상황
  • COVID-19가 중국의 경장영양 판매에 미치는 영향

제2장 중국내 경장영양 판매 동향(2016-2020년)

  • 경장영양 판매액
    • 전체적인 판매액
    • 지역별 판매액
  • 경장영양 판매량
    • 전체적인 판매량
    • 지역별 판매량
  • 중국내 경장영양 판매 동향 : 제형별(2016-2020년)
    • 현탁액(서스펜션)
    • 경구 분말
    • 경구 에멀전

제3장 중국의 주요 경장영양 제조업체 분석(2016-2020년)

  • 주요 경장영양 제조업체의 시장 점유율 분석
    • 시장 점유율 : 판매액 기반
    • 시장 점유율 : 판매량 기반
  • Niudi Xiya Pharmaceutical(Wuxi) Co.,ltd.
    • 기업 개요
    • 중국에서의 경장영양 판매 동향
  • Fresenius Kabi Deutschland GmbH
  • Fresenius Kabi Huarui Pharmaceutical Co., Ltd.
  • Abbott Laboratories BV
  • Milupa GmnH & Co KG

제4장 중국에서 경장영양의 가격 동향 : 주요 제조업체별(2020-2021년)

  • Niudi Xiya Pharmaceutical(Wuxi) Co.,ltd.(PEPTISON)
  • Fresenius Kabi Deutschland GmbH(FRESUBIN)
  • Fresenius Kabi Huarui Pharmaceutical Co., Ltd.(FRESUBIN DIABETES, FRESUBIN 750MCT, Ruineng)
  • Abbott Laboratories BV(JEVITY)
  • Milupa GmnH & Co KG(NUTRISON)

제5장 중국의 경장영양 시장 전망(2021-2025년)

  • 중국 경장영양 시장의 동향을 좌우하는 요인
    • 중국의 경장영양 시장에 대한 COVID-19의 영향
    • 시장의 촉진요인과 기회
    • 시장의 위협과 과제
  • 시장 규모의 예측
  • 시장 동향의 예측
KSA 21.07.07

List of Charts

  • Chart Patent Information About Enteral Nutrition Suspension Registration in China
  • Chart Patent Information About Enteral Nutrition Oral Powder Registration in China
  • Chart Patent Information About Enteral Nutrition Oral Emulsion Registration in China
  • Chart Sales Value of Enteral Nutrition Suspension over the World
  • Chart Sales Value of Enteral Nutrition Oral Powder over the World
  • Chart Sales Value of Enteral Nutrition Oral Emulsion over the World
  • Chart Sales Value of Enteral Nutrition Suspension in China, 2016-2020
  • Chart Sales Value of Enteral Nutrition Oral Powder in China, 2016-2020
  • Chart Sales Value of Enteral Nutrition Oral Emulsion in China, 2016-2020
  • Chart Sales Value of Enteral Nutrition Suspension in China by Region, 2016-2020
  • Chart Sales Value of Enteral Nutrition Oral Powder in China by Region, 2016-2020
  • Chart Sales Value of Enteral Nutrition Oral Emulsion in China by Region, 2016-2020
  • Chart Sales Volume of Enteral Nutrition Suspension in China, 2016-2020
  • Chart Sales Volume of Enteral Nutrition Oral Powder in China, 2016-2020
  • Chart Sales Volume of Enteral Nutrition Oral Emulsion in China, 2016-2020
  • Chart Sales Volume of Enteral Nutrition Suspension in China by Region, 2016-2020
  • Chart Sales Volume of Enteral Nutrition Oral Powder in China by Region, 2016-2020
  • Chart Sales Volume of Enteral Nutrition Oral Emulsion in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Enteral Nutrition Suspension Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Enteral Nutrition Oral Powder Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Enteral Nutrition Oral Emulsion Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of PEPTISON in China, 2016-2020
  • Chart Sales Value and Volume of FRESUBIN in China, 2016-2020
  • Chart Sales Value and Volume of FRESUBIN DIABETES, FRESUBIN 750MCT, Ruineng in China, 2016-2020
  • Chart Sales Value and Volume of JEVITY in China, 2016-2020
  • Chart Sales Value and Volume of NUTRISON in China, 2016-2020
  • Chart Referential Prices of PEPTISON in China by Region, 2020-2021
  • Chart Referential Prices of FRESUBIN in China by Region, 2020-2021
  • Chart Referential Prices of FRESUBIN DIABETES, FRESUBIN 750MCT, Ruineng in China by Region, 2020-2021
  • Chart Referential Prices of JEVITY in China by Region, 2020-2021
  • Chart Referential Prices of NUTRISON in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Enteral Nutrition Suspension in China, 2021-2025
  • Chart Forecast on Sales Value of Enteral Nutrition Oral Powder in China, 2021-2025
  • Chart Forecast on Sales Value of Enteral Nutrition Oral Emulsion in China, 2021-2025
  • Chart Forecast on Sales Volume of Enteral Nutrition Suspension in China, 2021-2025
  • Chart Forecast on Sales Volume of Enteral Nutrition Oral Powder in China, 2021-2025
  • Chart Forecast on Sales Volume of Enteral Nutrition Oral Emulsion in China, 2021-2025

Enteral nutrition is mainly used for preoperative feeding of patients with anorexia and related diseases, including mechanical gastrointestinal dysfunction, critical illness and malnutrition. It was developed by Fresenius Kabi and was China in 1995. Chinese market. By 2020, in addition to Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd., there are Fresenius Kabi Deutschland GmbH, Fresenius Kabi Huarui Pharmaceutical Co., Ltd., Abbott Laboratories BV, and Milupa GmnH & Co KG and other 8 manufacturers in China's Enteral Nutrition market.

According to CRI analysis, the sales value of Enteral Nutrition in China has grown steadily year by year from 2016 to 2019. In 2020, due to the impact of the COVID-19 epidemic on the hospital's overall diagnosis and treatment services, the sales value of Enteral Nutrition in China fell slightly, reached CNY1.155 billion in 2020. The CAGR of the sales value of Enteral Nutrition is about 6.5% from 2016 to 2020 in China.

CRI expects that with the effective relief of the COVID-19 epidemic, the sales of Enteral Nutrition in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Enteral Nutrition is widely used clinically. With the improvement and popularization of medical services in China, the demand for Enteral Nutrition will continue to increase, so the sales of Enteral Nutrition in China will maintain a growing trend.

Topics Covered:

  • The impact of COVID-19 on China's Enteral Nutrition market
  • Sales value of China's Enteral Nutrition 2016-2020
  • Competitive landscape of China's Enteral Nutrition market
  • Prices of Enteral Nutrition in China
  • Prices of Enteral Nutrition in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Enteral Nutrition market
  • Prospect of China's Enteral Nutrition market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Enteral Nutrition

  • 1.1 Indications for Enteral Nutrition
  • 1.2 Development of Enteral Nutrition in China
  • 1.3 Governmental Approval of Enteral Nutrition in China
  • 1.4 The Impact of COVID-19 on Enteral Nutrition sales in China

2 Sales of Enteral Nutrition in China, 2016-2020

  • 2.1 Sales Value of Enteral Nutrition
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Enteral Nutrition
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Enteral Nutrition by Dosage Form in China, 2016-2020
    • 2.3.1 Suspension
    • 2.3.2 Oral Powder
    • 2.3.3 Oral Emulsion

3 Analysis of Major Enteral Nutrition Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Enteral Nutrition Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of PEPTISON (Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd.'s Enteral Nutrition) in China
  • 3.3 Fresenius Kabi Deutschland GmbH
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of FRESUBIN (Fresenius Kabi Deutschland GmbH's Enteral Nutrition) in China
  • 3.4 Fresenius Kabi Huarui Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of FRESUBIN DIABETES, FRESUBIN 750MCT, Ruineng (Fresenius Kabi Huarui Pharmaceutical Co., Ltd.'s Enteral Nutrition) in China
  • 3.5 Abbott Laboratories BV
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of JEVITY (Abbott Laboratories BV's Enteral Nutrition) in China
  • 3.6 Milupa GmnH & Co KG
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of NUTRISON (Milupa GmnH & Co KG's Enteral Nutrition) in China

4 Prices of Enteral Nutrition for Different Manufacturers in China, 2020-2021

  • 4.1 Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd. (PEPTISON)
  • 4.2 Fresenius Kabi Deutschland GmbH (FRESUBIN)
  • 4.3 Fresenius Kabi Huarui Pharmaceutical Co., Ltd. (FRESUBIN DIABETES, FRESUBIN 750MCT, Ruineng)
  • 4.4 Abbott Laboratories BV (JEVITY)
  • 4.5 Milupa GmnH & Co KG(NUTRISON)

5 Prospect of Chinese Enteral Nutrition Market, 2021-2025

  • 5.1 Influential Factors of Chinese Enteral Nutrition Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Enteral Nutrition Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend
Back to Top
전화 문의
F A Q